Table 5.
Testing for significance of variation in β by various factors considered one at a time
| Factor | Level | Blocks includeda | Nb | β (95% CI) | Deviancec |
|---|---|---|---|---|---|
| None |
All |
1-32 |
32 |
0.018 (0.016-0.021) |
44.01 |
| Sex |
Male |
1,3-6,12-16,19,21,23-27,31 |
18 |
0.019 (0.016-0.022) |
42.33 |
| |
Female |
17,20,22,28-30 |
6 |
0.015 (0.008-0.022) |
|
| |
Both |
2,7-11,18,32 |
8 |
0.018 (0.012-0.024) |
|
| Publication year |
<1990 |
1,14,18-20,24 |
6 |
0.025 (0.012-0.038) |
40.12 |
| |
1990-1994 |
5,7-9,13,25-31 |
12 |
0.016 (0.012-0.020) |
|
| |
1995+ |
2-4,6,10-12,15-17,21-23,32 |
14 |
0.019 (0.016-0.023) |
|
| Mean age |
<50 |
5,6,11,12,14,15,19-21,31 |
10 |
0.024 (0.020-0.028) |
29.12** |
| |
50-59 |
1,3,4,9,13,16-18,25-30 |
14 |
0.015 (0.012-0.018) |
|
| |
60+ |
2,7,8,10,22-24,32 |
8 |
0.017 (0.011-0.022) |
|
| Quality score |
8 or 9 |
3,4,7-9,11-13,16,17,19,20,22,23, 25–30,32 |
21 |
0.017 (0.014-0.020) |
40.20 |
| |
5 to 7 |
1,2,5,6,10,14,15,18,21,24,31 |
11 |
0.022 (0.017-0.026) |
|
| Continent |
North America |
1,3,4,6-8,10-13,18-20,22-30,32 |
23 |
0.018 (0.014-0.021) |
43.46 |
| |
Other |
2,5,9,14-17,21,31 |
9 |
0.019 (0.016-0.023) |
|
| Disease fatality |
Deaths |
1,5,9,12,14,15,19-21,24,31 |
11 |
0.024 (0.020-0.027) |
28.99** |
| |
Incidence |
13,22,23,25-30 |
9 |
0.015 (0.011-0.020) |
|
| |
Both |
2-4,6-8,10,11,16-18,32 |
12 |
0.015 (0.012-0.019) |
|
| Population type |
General |
1,7-9,11,14,16,17,19-21,25-30 |
17 |
0.016 (0.013-0.019) |
37.74* |
| |
Other |
2-6,10,12,13,15,18,22-24,31,32 |
15 |
0.021 (0.018-0.025) |
|
| Exposed to lung carcinogens |
Yes |
3-6 |
4 |
0.016 (0.006-0.025) |
43.44 |
| |
No |
1,2,7-32 |
28 |
0.019 (0.016-0.021) |
|
| Follow-up period |
1-15 |
2,9,10,18-20,24,32 |
8 |
0.020 (0.013-0.027) |
41.72 |
| |
16-23 |
3-6,11,13,16,17,22,23,31 |
11 |
0.016 (0.012-0.021) |
|
| |
24+ |
1,7,8,12,14,15,21,25-30 |
13 |
0.019 (0.016-0.023) |
|
| Adjusted for smoking |
Yesd |
2-4,7-13,15-17,19,20,22-30,32 |
25 |
0.018 (0.016-0.021) |
43.98 |
| |
No |
1,5,6,14,18,21,31 |
7 |
0.019 (0.009-0.029) |
|
| Measure of FEV1 reported |
FEV1%P |
1-4,6-11,13,15-18,21-24,32 |
20 |
0.018 (0.015-0.021) |
43.93 |
| |
Other |
5,12,14,19,20,25-31 |
12 |
0.019 (0.014-0.024) |
|
| Weight of β |
<125 |
1,5-7,18-20,24,25,28,29 |
11 |
0.021 (0.010-0.031) |
43.54 |
| |
125-250 |
2,3,8,10,14,21-23,26,31,32 |
11 |
0.017 (0.012-0.023) |
|
| |
250+ |
4,9,11-13,15-17,27,30 |
10 |
0.019 (0.015-0.022) |
|
| Original data recorded as |
Regression coefficient |
7,8,10,22,23 |
5 |
0.017 (0.008-0.026) |
43.02 |
| |
RR (CI) |
1-4,9,11-13,15-18,21,24-30,32 |
21 |
0.018 (0.016-0.021) |
|
| SMR/SIR | 5,6,14,19,20,31 | 6 | 0.022 (0.011-0.034) |
a See Tables 3 and 4 for definition of blocks.
b Number of estimates of β which are combined.
c The significance of the factor is assessed by comparing the deviance for the model including that factor and the deviance for the null (no factor) model and is indicated by *p<0.05 **p<0.01 *** p<0.001.
d This includes blocks which relate to the whole population, current smokers or ever smokers which adjust at least for a measure of dose, such as cigs/day or pack yrs, and blocks which are restricted to nonsmokers.